智通财经APP讯,佰金生命科学(01466)发布公告,集团预期截至2026年3月31日止年度将取得亏损不超过4300万港元,而截至2025年3月31日止年度则取得亏损约为10万港元。集团截至2026年3月31日止年度的亏损大幅增加主要由于下列因素:收益及毛利减少,主要来自珠宝业务分部;及销售开支增加,主要来自护肤业务分部。
智通财经APP讯,佰金生命科学(01466)发布公告,集团预期截至2026年3月31日止年度将取得亏损不超过4300万港元,而截至2025年3月31日止年度则取得亏损约为10万港元。集团截至2026年3月31日止年度的亏损大幅增加主要由于下列因素:收益及毛利减少,主要来自珠宝业务分部;及销售开支增加,主要来自护肤业务分部。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.